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Abstract
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
probiotics are effective in reducing symptoms of atopic dermatitis.
STUDY DESIGN: Selective EBM review of three randomized, double-blind, placebo-controlled
trials published after 2009, all English language.
DATA SOURCES: All three studies were published in peer-reviewed journals found on PubMed
and selected based on relevance to the proposed clinical question.
OUTCOMES MEASURED: The main outcome measured was the percentage change in
SCORAD index to determine severity of atopic dermatitis before and after trial through objective
and subjective findings. Additional outcomes included DLQ index which was evaluated via 10
questions scored on a scale of 0-3, IDQOL and DFI questionnaires directed towards evaluating
quality of life through 10 questions scored from 0-3, and frequency and amount of corticosteroid
used.
RESULTS: Each study assessed the change in SCORAD when comparing the probiotic with the
placebo group in those with moderate-to-severe atopic dermatitis. Gerasimov et al. found a
SCORAD decrease of 33.7% in the probiotic group in comparison to a decrease of 19.4% in the
placebo group and no statistically significant decrease in corticosteroid use (p=0.130). IDQOL
and DFI decreased by 33% and 35.2% in the probiotic group and only by 19% and 23.8% in the
placebo group, respectively. Iemoli et al. found that SCORAD and DLQ at the end of the trial
was significantly reduced in the probiotic group (p = 0.001, p = 0.024, respectively). The study
done by Navarro-Lopez et al. found a SCORAD change of -83% (95% CI, -95% to -70%) in the
probiotic group and a change of -24% (95% CI, -36% to -11%) in the placebo group. Topical
steroid use in the probiotic arm (7.7%) was significantly less compared to the placebo arm
(10.8%).
CONCLUSION: This systematic review suggests that probiotics are effective only as an
adjunctive therapy in the reduction of clinical symptoms and topical corticosteroid use in atopic
dermatitis. However, further research is needed to assess exclusive reduction in subjective
symptoms.
KEY WORDS: Atopic dermatitis, probiotics
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INTRODUCTION
Atopic dermatitis (AD) is a skin disorder with a chronic, recurrent course characterized
by pruritus, inflammation, and skin barrier disruption. This condition typically manifests early
during childhood and often persists into adulthood. AD poses a significant impact on quality of
life as the pruritus can affect sleep quality and result in symptoms that may cause emotional
stress over the course of an individual’s life. Without proper care, the affected areas can harbor
colonization and infection by bacteria such as Staphylococcus aureus.1 This condition is
commonly associated with asthma and allergic rhinitis as they are all considered to be atopic
disorders.
There is great potential for clinical impact in the field of AD treatments as it is a
commonly diagnosed skin disorder. AD has a prevalence of approximately 3-10% in adults and
20% of children worldwide with about half of those cases being diagnosed within the first year
of life.2 Beyond the scope of the individual practitioner and patient, AD also poses a sizeable
portion of healthcare costs nationwide. The annual financial cost of AD is estimated to be $5.297
billion which includes direct (prescriptions, visits to the physician) and indirect costs
(absenteeism, decreased quality of life).3 These costs correlate with the fact that AD comprises a
great deal of healthcare visits each year. Although precise census data are not available for recent
years, it is estimated that 75% of individuals with AD visited a physician at least once in the last
year with AD being the prime focus of their visit.3
The heavy burden endured by practitioners and patients in treating AD is evident.
However, the exact cause of AD remains unknown. Current leading research points to a
mutation in the gene that produces filaggrin, a protein that maintains the integrity of the
superficial-most layer of skin.2,4 Without fully functional filaggrin, there is a greater propensity
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for the entrance of allergens and microbes coupled with greater loss of moisture, resulting in skin
that becomes dry easily and is more susceptible to infection.2,4 It is also thought that AD
develops from an excess of T helper 2 cells relative to T helper 1 cells, leading to an increase in
IgE and interleukins.2 This manifests in the patient as symptoms of dry, scaly skin, erythema,
pruritus, and open, crusty, or “weepy” sores.4
There are various methods of treating AD with each having specific indications. One of
the more common treatment modalities is the use of corticosteroids which can be administrated
topically or orally, with the latter being reserved for severe cases.2 Corticosteroids are indicated
for symptom reduction after an exacerbation and are not indicated for prevention of acute
episodes; however, there are a variety of preventative methods to reduce the occurrence of flares.
Skin hydration and emollients coupled with the avoidance of allergens and irritants are effective
towards preventing acute flares of AD. Less frequently used methods to treat AD include
Narrowband Ultraviolet B (UVB) Phototherapy and biologics/immunosuppressants such as
dupilumab.4
Unfortunately, there is currently no cure for AD. The treatment modalities listed above
play an effective role in preventing or reducing sequelae of flares, but AD is a recurrent
condition that may be a lifelong source of emotional stress on the patient. The treatment methods
are also not entirely benign as corticosteroids have a variety of undesirable side effects such as
stretch marks, and hypopigmentation and atrophy of skin, especially with prolonged use.4
Narrowband UVB phototherapy has a success rate of 70% in temporarily “remitting” AD, but it
is primarily used for widespread or refractory AD so the application is limited.4 While biologics
such as dupilumab have shown efficacy, there are a variety of barriers such as high out-of-pocket
costs, requirements to fail lower forms of therapy, and the necessity of prior authorization.4
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These are only some of the many reasons why probiotics have gained a great deal of traction as
an adjunctive therapy option to reduce symptoms of AD.
Probiotics have recently been targeted as a potential form of therapy in reducing AD
symptoms. One of the main reasons is due to the immunological benefits of probiotics. Research
has shown that AD patients tend to have a decreased innate immune response when compared
with similar skin conditions such as psoriasis.1 The microflora in the human gut has a significant
role in maintaining healthy immune function and as such, probiotics must be considered as a
method to improve this function. This paper evaluates three double-blind, placebo-controlled,
randomized controlled trials (RCTs) comparing the efficacy of various probiotic mixtures as a
potential treatment option for reduction of AD symptoms.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not probiotics are
effective in reducing symptoms of atopic dermatitis.
METHODS
Three double-blind, placebo-controlled RCTs were used in this study. The criteria to
select these studies included patients greater than 1 year of age with symptomatic moderate-tosevere atopic dermatitis. The interventions used in two of the studies were oral probiotic
mixtures,2,5 while one study used a probiotic sachet.2 The treatment group receiving the probiotic
mixture was compared to the control group who received a visually matched placebo.
All of the articles used in this study were published in peer-reviewed journals and
selected based on patient-oriented evidence that matters (POEMs) along with relevance to the
proposed clinical question. The articles were found by using the keywords “atopic dermatitis”
and “probiotics” via PubMed literature search. Only studies written in English were included in
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this review. The inclusion criteria included RCT, placebo-controlled, double-blind studies
published after 2009. The exclusion criteria included any patients under the age of 1 and those
with mild AD.
All three studies included in this systematic review used continuous data. The statistics
that were reported included change in mean from baseline and p-values. The Mann-Whitney U
test was used to assess Scoring of Atopic Dermatitis (SCORAD), Infant Dermatitis Quality of
Life (IDQOL), and Dermatitis Family Impact (DFI) scores in one of the studies.5 Table 1
illustrates the demographics and characteristics of the reviewed studies.
Table 1: Demographics and Characteristics of Included Studies.
Study

Type

Gerasimov5
(2010)

Double
blind
RCT

#
Pts
90

Age
(yrs)
1-3

Inclusion
Criteria
-Patients aged 1-3 years
old with moderate to
severe AD
-Parent or legal
guardian must
comprehend study
requirements and
provide informed
consent
-Direct telephone
access

Exclusion
W/
Criteria
D
-Mild AD
6
-Clinically
evident bacterial
lesions
-Use of systemic
corticosteroids
-Food allergy
besides egg or
cow’s milk
-Concomitant
disease
requiring
immunosuppress
ants or allergic
reactions

Interventions
Probiotic
mixture
(Lactobacillu
s acidophilus
DDS-1 and
Bifidobacteri
um lactis
UABLA-12
with fructooligosacchari
de in a rice
maltodextrin
powder) 1 g
BID
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Iemoli6
(2012)

Double
blind
RCT

48

-Group
A:
32.44 +
1.47
-Group
B:
30.91 +
2.79

-Adult men and women
with moderate to severe
AD

-Probiotic,
antibiotic, or
immune
modulating
agent usage 6
months before
the study
-Oral steroid
treatment usage
1 month before
enrollment

2

Probiotic
mixture
(Lactobacillu
s salivarius
and
Bifidobacteri
um breve
combination)
matched for
size, shape,
and volume BID

Navarro
-Lopez2
(2018)

Double
blind
RCT

50

4-17

-AD meeting the
Hanifin and Rajka
criteria and moderate
SCORAD index who
had been prescribed
topical steroids
-Current diet with a
Mediterranean Diet
Quality Index
(KIDMED) score >7
-Written informed
consent from parents or
a legal representative
(and the child if >12
years)

-Systemic
corticosteroid,
methotrexate,
cyclosporine, or
anti-TNF drug
use in the past 3
months,
antibiotics in the
past 2 weeks, or
concomitant
diagnosis of
gluten and/or
lactose
intolerance or
bacterial
infection.

3

Probiotic
(Bifidobacter
ium lactis
CECT 8145,
B longum
CECT 7347,
and
Lactobacillus
casei CECT
9104) QD

OUTCOMES MEASURED
Each of the three studies assessed changes in objective and subjective findings between
the probiotic and placebo group using the SCORAD index which was calculated with the
following formula: A/5 + 7B/2 + C.5 Objective findings included characteristics such as extent
and intensity of AD, while subjective symptoms included elements such as pruritus and sleep
loss. The SCORAD index questionnaire assessed the severity of AD, categorizing them as mild,
moderate, or severe. Each study had differing values indicating the severity of AD. For instance,
Gerasimov et al. categorized any score between 25-50 as moderate AD, while a score above 50
indicated severe AD.5 This study also implemented IDQOL and DFI questionnaires for the test
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subjects to complete. These questionnaires included ten questions specific to the infant or family
activity over the course of the previous week with each answer being graded from 0-3. A
minimum score of 0 and a maximum score of 30 is possible with the maximum score indicating
the worst quality of life or the greatest family impact.5 Lastly, corticosteroid use was documented
by the participants.
In the Lopez et al. study, the SCORAD index was assessed with a score of 20-40
indicating moderate AD. These were measured at the time of inclusion and every 4 weeks until
the end of follow-up period at week 12. As it was performed in the study by Gerosimov et al.,
this study measured the proportion of days that a topical steroid was used during flares within the
same 12 weeks of follow-up. A flare was defined as the use of a corticosteroid for at least 3
consecutive days and any corticosteroid use occurring less than 3 days was not included.2
In the Iemoli et al. study, the SCORAD index was scored as follows: 0-15 indicated mild
AD, 16-40 indicated moderate AD, and any score above 40 indicated severe AD.6 Another
outcome that was assessed was the Dermatology Quality of Life (DLQ) index which was
performed by the patient. The DLQ index has a minimum score of 0 and a maximum score of 30.
It is a 4-point scale ranging from 0-3 in which 0 indicates not at all, 1 indicates a little, 2
indicates a lot, and 3 indicates very much.6
RESULTS
All three RCT studies evaluated the effectiveness of various probiotic mixtures compared
to placebo on individuals with moderate-to-severe AD. Placebos in these studies were identical
to the probiotic in characteristics such as taste, smell, and/or visual appearance. Patients were
excluded if they had previously used antibiotics, immunomodulators, or systemic corticosteroids
in any of these studies.2,5,6 Continuous data were used for all three experiments and not
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convertible to dichotomous format. Each study determined data to be statistically significant if
the p-value was <0.05.
Two trials mentioned compliance with only one of those studies providing statistical
evidence.5 Gerasimov et al. reported that the placebo and probiotic group were 95% and 92%
compliant, respectively, with both groups receiving more than 90% of available doses
(p=0.723).5 This statistic was calculated through parental report and by measuring the probiotic
and placebo powder which remained at the end of the trial. Ieomoli et al. reported that
compliance was evaluated through a dose count but omitted results of such findings. Two trials
were in children over the age of 1, while one trial exclusively included adults.
The Gerasimov et al. study included children between the age of 1-3 with moderate-tosevere AD. Direct telephone and informed consent from a parent or legal guardian were also part
of the inclusion criteria as the participants were too young to provide consent on their own.5
Individuals excluded from this study included those with mild AD, bacterial lesions that were
clinically evident, food allergies excluding egg or cow’s milk, current systemic disease or cancer,
and immunodefiencies.5
The beginning of the experiment included 96 participants, however, by the week 8 mark,
5 were lost to follow-up in the experimental group while 1 was lost in the control group.5 The
experimental group of 43 patients received a probiotic mixture (DDS-1, UABLA-12 with fructooligosaccharide) twice a day for 8 weeks while the control group of 47 patients received a
placebo twice a day for 8 weeks.5 SCORAD, IDQOL, DFI, and corticosteroid use were
documented to evaluate the effectiveness of the probiotic in reducing symptoms of AD.
Statistical significance was observed when comparing SCORAD, IDQOL, and DFI at baseline
and week 8 of the trial (p=0.001. p=0.013, and p=0.010, respectively). This study found a
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statistically significant reduction in SCORAD at the end of the trial when assessing exclusively
subjective symptoms (pruritus, sleep loss). These findings fall in line with the overall SCORAD
decrease of 33.7% and 19.4% in the probiotic and placebo group, respectively.5 However, there
was no statistical significance with corticosteroid use per week (p=0.130) when comparing
baseline and week 8 findings.5 These findings are illustrated in Table 2 below.
Table 2: Change in mean at baseline and week 8 (Gerosimov et al.)
Time
Probiotic (SD)
Placebo (SD)
Period
SCORAD*
Baseline
8.7 (2.9)
8.0 (2.4)
Week 8
-3.0 (2.7)
-1.4 (2.0)
IDQOL
Baseline
11.2 (4.4)
12.1 (3.6)
Week 8
-3.7 (3.3)
-2.3 (1.6)
DFI
Baseline
12.2 (4.0)
12.6 (4.7)
Week 8
-4.3 (1.7)
-3.0 (2.7)
Corticosteroid use
Baseline
1.9
1.7
Week 8
0.8
1.2
*Assessing subjective symptoms (pruritus, sleep loss)
SD = standard deviation

p-value
0.001
0.013
0.010
0.130

The Iemoli et al. study included adult men and women with moderate-to-severe AD in
the setting of a hospital allergy unit. Individuals were excluded from the study if they had used
probiotics 6 months prior to the trial. A total of 48 patients were enrolled in the study and
separated into a probiotic and placebo group in a 2:1 ratio. A single patient was lost from each
group. The experimental group of 32 patients were administered with a probiotic mixture (LS01
and BR03 strains) taken twice daily for 12 weeks. The control group of 16 patients took a
placebo (maltodextrin) with the same regimen.
The SCORAD and DLQ questionnaire were addressed in this study with changes noted
in the probiotic and placebo group when compared at baseline to week 12 of the study. The
SCORAD at baseline for the probiotic group (46.25 +/- 3.70) and placebo group (45.00 +/-2.60)
were decreased at week 12 to 29.45 +/- 2.01 and 40.21 +/- 1.53, respectively.6 The probiotic
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group had significant decreases in SCORAD and DLQ at the end of treatment (p = 0.001, p =
0.024, respectively) and even 2 months after treatment (p = 0.006, p = 0.001, respectively).6 The
placebo group had no significant differences.
The Lopez et al. study was performed in an outpatient hospital and included children
between age 4-17 years old with moderate AD. It was required for participants to be currently on
a high-quality Mediterranean diet validated through the Mediterranean Diet Quality Index
(KIDMED). As with the previous study, participants required written consent from the parent or
legal representative due to age. Those excluded from the study included intolerance to gluten or
lactose as well as signs of bacterial infection.2
The study began with 50 participants, however, 2 were lost to follow-up at the 8-week
mark, while 1 was lost at the 12-week follow-up in the experiment group. This study examined
the change in SCORAD score and corticosteroid use between the experimental and control
group. The experimental group of 26 patients were instructed to take a probiotic (CECT
8145, CECT 7347, and CECT 9104) once daily for 12 weeks.2 The control group of 24 patients
took a placebo (maltodextrin) once daily for the same amount of time and was matched in
appearance and route of administration to the probiotic. Lopez et al. reported a significant
improvement in the total SCORAD score among the probiotic group when compared to the
placebo group. The total SCORAD combined objective findings (intensity and spread of eczema)
and subjective symptoms (pruritus, sleep loss) in the report. However, subjective symptoms are
the only factor of statistical importance in this review. There was an insufficient amount of data
provided in this study as the only conclusive finding was a report of no statistically significant
difference in subjective symptoms between the probiotic and placebo group.

Kim, Atopic Dermatitis and Probiotics, 10
Lopez et al. found a statistically significant reduction in the use of corticosteroids during
flares among the probiotic group. An adjusted logistic regression model was used to calculate the
odds ratio (OR) to be 0.63 with a confidence interval (CI) of 95% [0.51 to 0.78]. The data
favored probiotics even when a sensitivity analysis was performed to account for steroid use
which included non-flare scenarios (defined as less than 3 consecutive days of corticosteroid
use). In this situation, the placebo and probiotic arm had 336 (16.5%) and 291 (14.0%) days of
steroid use, respectively.2 In this case, the OR was 0.77 with a CI of 95% [0.65 to 0.91] and pvalue <0.003. The findings are illustrated in Table 3 below.
Table 3: Corticosteroid use in a flare (Lopez et al.)
Patient-days of
Days of steroid
observation
use to treat
flares
Probiotic

2084

161 (7.7%)

Placebo

2032

220 (10.8%)

Odds Ratio;
[CI 95%]

p-value

0.63 [0.51 to
0.78]

<0.001

DISCUSSION
Probiotics offer a safe option in reducing symptoms of AD as they have an extensive
history of being safe to use in healthy individuals.7 In fact, of the three studies in this review,
only one mentioned adverse effects such as diarrhea, constipation, and upper respiratory
infection with none of these being linked to the probiotics used in the study.5 The exception to
safe probiotic use is with severely ill and immunocompromised individuals who may experience
greater side effects.7
In the review of these studies, a major limitation was in the assessment of the SCORAD
index. The SCORAD evaluates objective findings, or disease-oriented outcomes, in addition to
subjective symptoms, patient-oriented outcomes. For the purpose of this review paper, the latter
is the focus which includes effects on pruritus and sleep loss. The combination of both categories
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of symptoms makes it difficult to assess whether subjective, patient-oriented outcomes are truly
being improved with the use of probiotics. Only two of the three studies in this review separated
subjective and objective elements of the SCORAD with one of those studies finding statistically
significant reduction in subjective symptoms,5 and the other noting insignificant symptom
reduction between the probiotic and placebo group.2
It is important for studies to control outside factors that can influence the results of a
study. This was seen in the Lopez et al. study which mandated a high-quality Mediterranean diet.
However, the data could have been more accurate with diary documentation of additional habits
that may influence the course of AD such as exercise, brand of laundry detergent or soaps, and
even moisturizing routine. These are all precipitating factors that have been proven to cause
acute exacerbations of AD.4 It is apparent that these controls would be more difficult in studies
exclusively involving children as it would require a great deal of compliance and responsibility
in the hands of both the participant and the parent or legal representative.
CONCLUSION
These studies provide evidence that probiotics can be used as an effective adjunctive
therapy in those with moderate-to-severe AD. While it will not have efficacy as monotherapy,
the studies in this review have demonstrated a reduction of symptoms when taken along with
other standard medications such as topical corticosteroids. In addition to being effective in
reducing symptoms, it was also shown to significantly reduce the need for corticosteroid use in
two of the studies.2,5 While all three of these studies found improvement in SCORAD overall,
more research must be done focusing strictly on subjective symptoms given that this index also
factors in objective signs.
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